All Stories

  1. Determinants of vaccine hesitancy among healthcare workers in an international multicenter study within the EuCARE project
  2. Activation of nuclear receptors correlates with tuberculosis severity and is a target for host-directed therapy
  3. Unlocking the Gates: A Novel Diagnostic Molecule for Quantifying Efflux Levels in Gram‐Positive Bacteria
  4. Evaluation of Amlodipine and Imipramine Efficacy to Treat Galleria mellonella Infection by Biofilm-Producing and Antimicrobial-Resistant Staphylococcus aureus
  5. Dissemination of arr-2 and arr-3 is associated with class 1 integrons in Klebsiella pneumoniae clinical isolates from Portugal
  6. Molecular Patterns and Antimicrobial Resistance Characterization of Salmonella enterica Non-Typhoidal from Human, Food, and Environment Samples Isolated in Luanda, Angola
  7. Preliminary structure−activity relationships analysis on N-(3,5-dichlorophenyl)-4,5-dihydronaphtho[1,2-d]thiazol-2-amine, a disruptor of mycobacterial energetics
  8. Sensitivity profile of pathogens identified in the diagnosis of urinary infection by uroculture carried out at the National Institute for Health Research, Luanda/Angola, during the pre - pandemic, intra - pandemic and post - pandemic of COVID 19
  9. The performance of Xpert MTB/RIF and MTBDRplus within a Programmatic setting at TB Laboratory in Rio de Janeiro, Brazil
  10. Antimicrobial resistance, society and environment: A glocal syndemic
  11. Towards clinical breakpoints for non-tuberculous mycobacteria – Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution
  12. Occurrence and Variability of the Efflux Pump Gene norA across the Staphylococcus Genus
  13. In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis
  14. Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs
  15. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
  16. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
  17. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
  18. The Neglected Contribution of Streptomycin to the Tuberculosis Drug Resistance Problem
  19. Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities
  20. Whole-genome sequencing as a tool for studying the microevolution of drug-resistant serial Mycobacterium tuberculosis isolates
  21. Electrochemical Detection of Single-Nucleotide Polymorphism Associated with Rifampicin Resistance in Mycobacterium tuberculosis Using Solid-Phase Primer Elongation with Ferrocene-Linked Redox-Labeled Nucleotides
  22. Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment
  23. Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil
  24. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
  25. Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis
  26. Short Communication: HIV and Tuberculosis Co-Infection Among Migrants in Portugal: A Brief Study on Their Sociodemographic, Clinical, and Genomic Characteristics
  27. Measuring Efflux and Permeability in Mycobacteria
  28. Author Correction: Genomic epidemiology of Mycobacterium tuberculosis in Santa Catarina, Southern Brazil
  29. Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates – the EUCAST broth microdilution reference method for MIC determination
  30. What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?
  31. Anti-staphylococcal activity and mode of action of thioridazine photoproducts
  32. Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?
  33. Genomic epidemiology of Mycobacterium tuberculosis in Santa Catarina, Southern Brazil
  34. Epidemic and pandemic viral infections: impact on tuberculosis and the lung
  35. Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs
  36. ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance
  37. Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents
  38. The role of mini-bronchoalveolar lavage fluid in the diagnosis of pulmonary tuberculosis in critically ill patients
  39. First insights into circulating XDR and pre-XDR Mycobacterium tuberculosis in Southern Brazil
  40. Using genomics to understand the origin and dispersion of multidrug and extensively drug resistant tuberculosis in Portugal
  41. Emergence of multidrug-resistant Mycobacterium tuberculosis of the Beijing lineage in Portugal and Guinea-Bissau: a snapshot of moving clones by whole-genome sequencing
  42. Detection of Drug Resistant Mycobacterium Tuberculosis Strains Using Kit SIRE Nitratase®: a Multicenter Study
  43. The Contribution of Efflux Pumps in Mycobacterium abscessus Complex Resistance to Clarithromycin
  44. Experimental Evidence for Limited in vivo Virulence of Mycobacterium africanum
  45. In silico and in vitro evaluation of tetrahydropyridine compounds as efflux inhibitors in Mycobacterium abscessus
  46. Genetic Diversity and Molecular Epidemiology of Mycobacterium tuberculosis in Roraima State, Brazil
  47. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs
  48. Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections
  49. Tuberculosis care for migrant patients in Portugal: a mixed methods study with primary healthcare providers
  50. Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals lineage-specific associations with drug resistance
  51. Modifications on C6 and C7 positions of 3-phenylquinolone efflux pump inhibitors led to potent and safe anti-mycobacterial treatment adjuvants
  52. Insights on the Mycobacterium tuberculosis population structure associated with migrants from Portuguese-speaking countries over a three-year period in greater Lisbon, Portugal: Implications at the public health level
  53. Genetic Diversity of norA, Coding for a Main Efflux Pump of Staphylococcus aureus
  54. Tetrahydropyridine derivative as efflux inhibitor in Mycobacterium abscessus
  55. Large expert-curated database for benchmarking document
  56. A case report of disseminated Mycobacterium colombiense infection in an HIV patient
  57. Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance
  58. Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence
  59. Advances in the molecular diagnosis of tuberculosis: From probes to genomes
  60. Innovative Implementation of Antibiotic Stewardship supported by a Clinical Decision System
  61. Innovative Implementation of Antibiotic Stewardship supported by a Clinical Decision System
  62. Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation
  63. Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics
  64. Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data
  65. Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
  66. Participatory-Implementation of an antibiotic stewardship programme supported by an innovative surveillance and clinical decision-support system
  67. Antimicrobial and Efflux Inhibitor Activity of Usnic Acid Against Mycobacterium abscessus
  68. Fighting antibiotic resistance in Portuguese hospitals: Understanding antibiotic prescription behaviours to better design antibiotic stewardship programmes
  69. Activity of Rifabutin and Hemi-synthetic Derivatives Against Mycobacterium abscessus
  70. Contribution of efflux to colistin heteroresistance in a multidrug resistant Acinetobacter baumannii clinical isolate
  71. Emergence of High-Level Colistin Resistance in an Acinetobacter baumannii Clinical Isolate Mediated by Inactivation of the Global Regulator H-NS
  72. Author Correction: Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis
  73. 4.10-P12Perspectives of health care providers in Portugal on the provision of care to migrant patients with TB or HIV-TB co-infection
  74. Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains
  75. Clonal expansion across the seas as seen through CPLP-TB database: A joint effort in cataloguing Mycobacterium tuberculosis genetic diversity in Portuguese-speaking countries
  76. First report on antimicrobial resistance and molecular characterization of Salmonella enterica serotype Typhi isolated from human specimens in Luanda, Angola
  77. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis
  78. Methylation in Mycobacterium tuberculosis is lineage specific with associated mutations present globally
  79. Insights on the Mechanism of Action of INH-C10 as an Antitubercular Prodrug
  80. Active antimicrobial efflux in Staphylococcus epidermidis: building up of resistance to fluoroquinolones and biocides in a major opportunistic pathogen
  81. Role of Alanine Racemase Mutations in Mycobacterium tuberculosisd-Cycloserine Resistance
  82. HIV and tuberculosis co-infection among migrants in Europe: A systematic review on the prevalence, incidence and mortality
  83. Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium
  84. Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery
  85. Synthesis and Biological Evaluation of Hybrid 1,5- and 2,5-Disubstituted Indoles as Potentially New Antitubercular Agents
  86. Detection of tuberculosis drug resistance: a comparison by Mycobacterium tuberculosis MLPA assay versus Genotype®MTBDRplus
  87. Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis
  88. Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against Escherichia coli
  89. Política de Investigação Científica para a Saúde em Portugal: II – Factos e Sugestões
  90. In vitro and in silico analysis of the efficiency of tetrahydropyridines as drug efflux inhibitors in Escherichia coli
  91. Política de Investigação Científica para a Saúde em Portugal: I - Enquadramento Europeu e Nacional
  92. Genetic diversity, transmission dynamics and drug resistance of Mycobacterium tuberculosis in Angola
  93. Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action
  94. The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs
  95. Genetic diversity, transmission dynamics, and drug resistance of Mycobacterium tuberculosis in Luanda, Angola
  96. An Experimental Model for the Rapid Screening of Compounds with Potential Use Against Mycobacteria
  97. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives
  98. Beyond extensively drug-resistant tuberculosis in lisbon, portugal: a case of linezolid resistance acquisition presenting as an iliopsoas abscess
  99. Plasmid-Borne Antimicrobial Resistance ofStaphylococcus aureusIsolated in a Hospital in Lisbon, Portugal
  100. Prevention and Control of Antimicrobial Resistant Healthcare-Associated Infections: The Microbiology Laboratory Rocks!
  101. Recombination in pe/ppe genes contributes to genetic variation in Mycobacterium tuberculosis lineages
  102. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis
  103. Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter
  104. Efflux Pumps in Mycobacteria: Antimicrobial Resistance, Physiological Functions, and Role in Pathogenicity
  105. Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against Mycobacterium smegmatis and Mycobacterium avium
  106. Impact of efflux in the development of multidrug resistance phenotypes in Staphylococcus aureus
  107. The Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant Phenotype
  108. Multidrug-Resistant Mycobacterium tuberculosis of the Latin American Mediterranean Lineage, Wrongly Identified as Mycobacterium pinnipedii (Spoligotype International Type 863 [SIT863]), Causing Active Tuberculosis in South Brazil
  109. Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy
  110. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences
  111. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa
  112. Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil
  113. Enhancing activity of antibiotics against Staphylococcus aureus: Zanthoxylum capense constituents and derivatives
  114. Genomic diversity of drug-resistant Mycobacterium tuberculosis isolates in Lisbon Portugal: Towards tuberculosis genomic epidemiology
  115. Measuring Efflux and Permeability in Mycobacteria
  116. Rapid identification of veterinary-relevant Mycobacterium tuberculosis complex species using 16S rDNA, IS6110 and Regions of Difference-targeted dual-labelled hydrolysis probes
  117. Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting
  118. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study
  119. Zanthoxylum capense constituents and derivatives: Effects on the activity of antibiotics against Staphylococcus aureus strains
  120. Nested and Multiplex Real-Time PCR Using Dual-Labeled Probes: Detecting and Discriminating Mycobacterium tuberculosis Complex Members in Cultures and Animal Tissues
  121. Standing of nucleic acid testing strategies in veterinary diagnosis laboratories to uncover Mycobacterium tuberculosis complex members
  122. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains
  123. Relatedness of Mycobacterium avium subspecies hominissuis clinical isolates of human and porcine origins assessed by MLVA
  124. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity
  125. PolyTB: A genomic variation map for Mycobacterium tuberculosis
  126. Gold nanoprobes for multi loci assessment of multi-drug resistant tuberculosis
  127. GidB mutation as a phylogenetic marker for Q1 cluster Mycobacterium tuberculosis isolates and intermediate-level streptomycin resistance determinant in Lisbon, Portugal
  128. Membrane transport systems and the biodegradation potential and pathogenicity of genus Rhodococcus
  129. Spectinamides: a challenge, a proof, and a suggestion
  130. Assessment of the BD MGIT TBc Identification Test for the Detection ofMycobacterium tuberculosisComplex in a Network of Mycobacteriology Laboratories
  131. Enhanced Detection of Tuberculous Mycobacteria in Animal Tissues Using a Semi-Nested Probe-Based Real-Time PCR
  132. QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
  133. Generation and biological evaluation of the products formed from the exposure of Phenothiazine to a 266nm laser beam
  134. Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis
  135. Description of plasmid pSM52, harbouring the gene for the Smr efflux pump, and its involvement in resistance to biocides in a meticillin-resistant Staphylococcus aureus strain
  136. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations
  137. Multidrug Efflux Pumps in Staphylococcus aureus: an Update
  138. A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps
  139. Resistance to Antimicrobials Mediated by Efflux Pumps in Staphylococcus aureus
  140. Correction: Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus
  141. Isothermal DNA amplification coupled to Au-nanoprobes for detection of mutations associated to Rifampicin resistance in Mycobacterium tuberculosis
  142. Role of the Mmr Efflux Pump in Drug Resistance in Mycobacterium tuberculosis
  143. From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition
  144. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs
  145. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex
  146. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections
  147. Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis
  148. Gold on paper–paper platform for Au-nanoprobe TB detection
  149. Genetic response of Salmonella enterica serotype Enteritidis to thioridazine rendering the organism resistant to the agent
  150. Synthesis and thermochemical study of quinoxaline-N-oxides: enthalpies of dissociation of the N-O bond
  151. Ethidium bromide efflux by Salmonella: modulation by metabolic energy, pH, ions and phenothiazines
  152. Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation
  153. Antibacterial properties of compounds isolated from Carpobrotus edulis
  154. Effective Therapy with the Neuroleptic Thioridazine as an Adjunct to Second Line of Defence Drugs, and the Potential that Thioridazine Offers for New Patents that Cover a Variety of “New Uses”
  155. Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors
  156. Role of calcium in the efflux system of Escherichia coli
  157. Ethidium bromide transport across Mycobacterium smegmatiscell-wall: correlation with antibiotic resistance
  158. Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient
  159. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus
  160. Inhibition of efflux pumps in meticillin-resistant Staphylococcus aureus and Enterococcus faecalis resistant strains by triterpenoids from Momordica balsamina
  161. Identification of the plasmid-encoded qacA efflux pump gene in meticillin-resistant Staphylococcus aureus (MRSA) strain HPV107, a representative of the MRSA Iberian clone
  162. Physiological characterisation of the efflux pump system of antibiotic-susceptible and multidrug-resistant Enterobacter aerogenes
  163. Au-nanoprobes for detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis
  164. Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains
  165. Identification of nontuberculous mycobacteria in clinical samples using molecular methods: a 3-year study
  166. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
  167. Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections
  168. Identification of Efflux-Mediated Multi-drug Resistance in Bacterial Clinical Isolates by Two Simple Methods
  169. Evaluation of Efflux Activity of Bacteria by a Semi-automated Fluorometric System
  170. The role of efflux pumps in macrolide resistance in Mycobacterium avium complex
  171. An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators
  172. pH Modulation of Efflux Pump Activity of Multi-Drug Resistant Escherichia coli: Protection During Its Passage and Eventual Colonization of the Colon
  173. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB)
  174. Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli
  175. New Methods for the Identification of Efflux Mediated MDR Bacteria, Genetic Assessment of Regulators and Efflux Pump Constituents, Characterization of Efflux Systems and Screening for Inhibitors of Efflux Pumps
  176. Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps
  177. Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide
  178. Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method
  179. The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics
  180. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis
  181. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities
  182. Enhanced Killing of Intracellular Pathogenic Bacteria by Phenothiazines and the Role of K+ Efflux Pumps of the Bacterium and the Killing Macrophage
  183. Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents
  184. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps
  185. Antibiotic Stress, Genetic Response and Altered Permeability of E. coli
  186. Prolonged exposure of methicillin-resistant Staphylococcus aureus (MRSA) COL strain to increasing concentrations of oxacillin results in a multidrug-resistant phenotype
  187. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis
  188. Antibacterial activity of ergosterol peroxide againstMycobacterium tuberculosis: dependence upon system and medium employed
  189. "Non-Antibiotics": Alternative Therapy for the Management of MDRTB and MRSA in Economically Disadvantaged Countries
  190. Reserpine, Ouabain and the Calcium Channel Blocker Verapamil, Cause Intracellular Killing of Staphylococcus aureus
  191. Direct Application of the INNO-LiPA Rif.TB Line-Probe Assay for Rapid Identification of Mycobacterium tuberculosis Complex Strains and Detection of Rifampin Resistance in 360 Smear-Positive Respiratory Specimens from an Area of High Incidence of Multid...
  192. Inducement and Reversal of Tetracycline Resistance in Escherichia coli K-12 and Expression of Proton Gradient-Dependent Multidrug Efflux Pump Genes
  193. Gamma delta T cell responses associated with the development of tuberculosis in health care workers
  194. Exogenous Re-infection by Multiple Exposures to Mycobacterium tuberculosis Contributes to Subsequent Development of Active Tuberculosis
  195. Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus
  196. Since phenothiazines alter antibiotic susceptibility of microorganisms by inhibiting efflux pumps, are these agents useful for evaluating similar pumps in phenothiazine-sensitive parasites?
  197. Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro
  198. Mycobacterial efflux pumps and chemotherapeutic implications
  199. Foreword
  200. Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant Mycobacterium tuberculosis
  201. Carpobrotus edulis methanol extract inhibits the MDR ef?ux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation
  202. Isoniazid-Induced Transient High-Level Resistance in Mycobacterium tuberculosis
  203. Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus
  204. Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations
  205. Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries
  206. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy
  207. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines
  208. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis
  209. Structural and functional analysis of the gene cluster encoding carotenoid biosynthesis in Mycobacterium aurum A+
  210. Structural and functional analysis of the gene cluster encoding carotenoid biosynthesis in Mycobacterium aurum A+
  211. Growth increments and biomineralization process in cephalopod statoliths
  212. Mycobacteriophage D29 contains an integration system similar to that of the temperate mycobacteriophage L5
  213. Pesquisa de infecção micobacteriana em hemoculturas de doentes com SIDA, usando o sistema BACTEC 460TB
  214. Improving on the LJ slope - automated liquid culture.
  215. Therapy of the XDR-TB patient with thioridazine - an old drug with new applications.